Real-World Treatment Patterns and Outcomes of Growth Hormone Treatment Among Children in Israel Over the Past Decade (2004-2015)
- PMID: 34490167
- PMCID: PMC8418062
- DOI: 10.3389/fped.2021.711979
Real-World Treatment Patterns and Outcomes of Growth Hormone Treatment Among Children in Israel Over the Past Decade (2004-2015)
Abstract
Objective: To assess a decade of growth hormone (GH) treatment patterns and outcomes in a real-world setting in Israel using a state-of-the-art computerized database. Methods: This large retrospective database study included 2,379 children initiating GH treatment in Maccabi Healthcare Services (between January 2004 and December 2014). Good adherence with therapy (proportion of days covered >80%) was assessed during follow-up. Results: At GH treatment initiation: 62.1% were boys; height standard deviation score (SDS) was -2.36 ± 0.65 (mean ± SD); age was 9.8 ± 3.1 years; and time from short stature diagnosis to first GH purchase was 4.8 ± 3.3 years. Mean treatment period was 3.5 ± 0.95 years; 79.4% of children were treated for more than 3 years. The two main indications for GH therapy were idiopathic short stature (ISS) (n = 1,615, 67.9%) and GH deficiency (GHD) (n = 611, 25.7%). Children in the highest socio-economic-status (SES) tertile comprised 61.3% of ISS and 59.7% of GHD. After 3 years, mean height gain SDS was 1.09 ± 0.91 for GHD and 0.96 ± 0.57 for ISS (p = 0.0004). Adult height (age 15 for girls and 17 for boys) was recorded for 624 patients (26.2%) with better outcomes for GHD than ISS (-1.0±0.82 vs. -1.28±0.93, respectively; p = 0.0002). Good adherence was achieved in 78.2% of the cohort during the first year and declined thereafter to 68.1% during the third year of the treatment. Conclusions: Children who initiate GH therapy are predominantly male, belong mainly to the upper SES, commence treatment a long period after initial recognition of short stature, and have suboptimal adherence. Appropriate referral, diagnosis, and follow-up care may result in better treatment outcomes with GH therapy.
Keywords: children; growth; growth hormone; growth hormone deficiency; height; idiopathic short stature.
Copyright © 2021 Ben-Ari, Chodick, Shalev, Goldstein, Gomez and Landau.
Conflict of interest statement
RG is an employee and/or stockholder of Pfizer. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that this study received funding from Pfizer. The funder was involved in study design and preparation of the manuscript for publication. Editorial/medical writing support was provided by Sharmy Blows, PhD, of Engage Scientific Solutions and was funded by Pfizer.
Figures



Similar articles
-
Is the growth outcome of children with idiopathic short stature and isolated growth hormone deficiency following treatment with growth hormone and a luteinizing hormone-releasing hormone agonist superior to that obtained by GH alone?J Pediatr Endocrinol Metab. 2012;25(7-8):651-7. doi: 10.1515/jpem-2012-0182. J Pediatr Endocrinol Metab. 2012. PMID: 23155689
-
Height Gain and Safety Outcomes in Growth Hormone-Treated Children with Idiopathic Short Stature: Experience from a Prospective Observational Study.Horm Res Paediatr. 2019;91(4):241-251. doi: 10.1159/000500087. Epub 2019 Jun 11. Horm Res Paediatr. 2019. PMID: 31185471 Clinical Trial.
-
Responses to growth hormone (GH) therapy in short children with normal GH secretion and no bone age delay: an analysis of potential factors affecting their response to rhGH therapy. A controlled study.Acta Biomed. 2019 Sep 23;90(8-S):43-51. doi: 10.23750/abm.v90i8-S.8506. Acta Biomed. 2019. PMID: 31544806 Free PMC article.
-
The growth hormone cascade: progress and long-term results of growth hormone treatment in growth hormone deficiency.Horm Res. 1998;49 Suppl 2:41-57. doi: 10.1159/000053087. Horm Res. 1998. PMID: 9730672 Review.
-
Growth hormone treatment of idiopathic short stature.Horm Res. 1996;46(4-5):208-14. doi: 10.1159/000185025. Horm Res. 1996. PMID: 8950623 Review.
Cited by
-
Adherence to Growth Hormone Treatment in Children During the COVID-19 Pandemic.J Clin Res Pediatr Endocrinol. 2024 Sep 5;16(3):256-263. doi: 10.4274/jcrpe.galenos.2024.2023-10-8. Epub 2024 Mar 15. J Clin Res Pediatr Endocrinol. 2024. PMID: 38488049 Free PMC article.
-
Effect of long-acting PEGylated growth hormone for catch-up growth in children with idiopathic short stature: a 2-year real-world retrospective cohort study.Eur J Pediatr. 2024 Oct;183(10):4531-4539. doi: 10.1007/s00431-024-05719-9. Epub 2024 Aug 19. Eur J Pediatr. 2024. PMID: 39158594 Free PMC article.
-
Rationale for Long-acting Growth Hormone Therapy and Future Aspects.J Clin Res Pediatr Endocrinol. 2025 Mar 19;17(1):1-8. doi: 10.4274/jcrpe.galenos.2024.2023-11-8. Epub 2024 Mar 15. J Clin Res Pediatr Endocrinol. 2025. PMID: 38488050 Free PMC article. Review.
-
Recombinant growth hormone therapy in children with short stature in Abu Dhabi: a cross-sectional study of indications and treatment outcomes.Front Pediatr. 2025 May 20;13:1516967. doi: 10.3389/fped.2025.1516967. eCollection 2025. Front Pediatr. 2025. PMID: 40464049 Free PMC article.
-
Height outcomes in Korean children with idiopathic short stature receiving growth hormone treatment.Front Endocrinol (Lausanne). 2022 Sep 7;13:925102. doi: 10.3389/fendo.2022.925102. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36157444 Free PMC article.
References
-
- Audi L, Fernandez-Cancio M, Camats N, Carrascosa A. Growth hormone deficiency: an update. Minerva Endocrinol. (2013) 38:1–16. - PubMed
-
- Deal C, Hasselmann C, Pfaffle RW, Zimmermann AG, Quigley CA, Child CJ, et al. . Associations between pituitary imaging abnormalities and clinical and biochemical phenotypes in children with congenital growth hormone deficiency: data from an international observational study. Horm Res Paediatr. (2013) 79:283–92. 10.1159/000350829 - DOI - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous